A system that uses artificial intelligence (AI) to detect diabetic retinopathy without a person interpreting the results earned Food and Drug Administration (FDA) authorization in April, following a clinical trial in primary care offices. The study was the first to prospectively assess the safety of an autonomous AI system in patient care settings.